EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysis

Albertus Ari Adrianto iD, Ignatius Riwanto, Udadi Sadhana, Dewi Kartikawati Paramita iD, Henry Setyawan, Kevin Christian Tjandra iD, Danendra Rakha Putra Respati iD, Derren David Christian Homenta Rampengan, Roy Novri Ramadhan, Gastin Gabriel Jangkang, Endang Mahati iD, Patricia Winona

PLOS One · 2025

DOI: 10.1371/journal.pone.0307128 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS One, 2025. Verfasst von Albertus Ari Adrianto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antibodies, Monoclonal, Humanized, Nivolumab, Ipilimumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer ( CRC ) is the third leading cause of cancer-related deaths worldwide, with cases expected to rise 60% by 2030, especially in Asia. Metastatic CRC (mCRC) has a poor 5-year survival rate of 14%, posing a major treatment challenge. Tumors with DNA mismatch repair deficiency (dMMR) and a high level of microsatellite instability (MSI-H) respond well to immune checkpoint inhibitors ( ICIs ), shifting treatment strategies. This systematic review and meta-analysis evaluate Pembrolizumab (PEM), Nivolumab (NIV), and Nivolumab plus Ipilimumab (NIV + IPI) for their promising antitumor efficacy in MSI-H/dMMR mCRC.

Methods

This systematic review followed PRISMA guidelines and Cochrane Handbook standards, covering studies from 2014 to 2024 on advanced CRC patients treated with ICIs. A comprehensive search across eight databases was conducted by 12 independent reviewers. Extracted outcomes included overall survival ( OS ), progression-free survival ( PFS ), disease control rate ( DCR ), and objective response rate ( ORR ). To facilitate pooled analysis, data reported as median and interquartile range ( IQR ), or median, minimum, and maximum were converted to mean and standard deviation ( SD ) using combined formulas by Luo D et al. and Wan X et al. Risk of bias was assessed using the Cochrane RoB 2 tool. Meta-analyses were performed using random-effects models, with subgroup analyses by dosage. Publication bias and sensitivity analyses were conducted. All statistical analyses used RevMan version 5.4.

Results

A total of 13 eligible studies were analyzed, with sample sizes ranging from 11 to 307 and follow-up durations between 5.3 and 44.5 months. NIV + IPI showed the highest efficacy across all endpoints: ORR 0.54 [95% CI: 0.45–0.65, I² = 75%], OS 0.84 [95% CI: 0.81–0.88, I² = 0%], PFS 0.73 [95% CI: 0.68–0.78, I² = 0%], and DCR 0.82 [95% CI: 0.77–0.86, I² = 0%]. This combination outperformed NIV alone, which demonstrated ORR 0.36 [95% CI: 0.21–0.60, I² = 81%], OS 0.73 [95% CI: 0.62–0.86, I² = 54%], PFS 0.54 [95% CI: 0.43–0.68, I² = 34%], and DCR 0.70 [95% CI: 0.64–0.77, I² = 0%]. PEM showed lower efficacy with ORR 0.33 [95% CI: 0.23–0.49, I² = 94.6%], OS 0.59 [95% CI: 0.31–0.66, I² = 94%], PFS 0.45 [95% CI: 0.31–0.66, I² = 84%], and DCR 0.73 [95% CI: 0.47–1.12, I² = 94%]. PEM’s 200 mg dosage subgroup exhibited the best performance in its group with an ORR of 0.45 [95% CI: 0.38–0.52, I² = 0%]. Despite these findings, heterogeneity was notably high in PEM-related studies, highlighting variability in populations and study designs. Overall, NIV + IPI demonstrated superior and more consistent clinical outcomes.

Conclusions

This study highlights NIV + IPI as a promising combination for advanced CRC, showing superior efficacy, while PEM also demonstrated potential. However, high heterogeneity suggests the need for further research. Acknowledging its limitations, this study marks a pioneering effort in comparing short- and long-term effects of anti-CTLA-4 and anti-PD-1 therapies, paving the way for future advancements in CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntibodies, Monoclonal, HumanizedNivolumabIpilimumabAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansTreatment OutcomeImmune Checkpoint InhibitorsMicrosatellite Instability

Substanzen

Antibodies, Monoclonal, HumanizedNivolumabpembrolizumabIpilimumabAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia.
  • Department of Anatomical Pathology, Faculty of Medicine, Universitas Diopnegoro, Semarang, Indonesia.
  • Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Study Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Department of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang, Indonesia.

ORCID-Profile: Albertus Ari Adrianto, Dewi Kartikawati Paramita, Kevin Christian Tjandra, Danendra Rakha Putra Respati, Endang Mahati

Zitieren

APA

Adrianto, A. A., Riwanto, I., Sadhana, U., Paramita, D. K., Setyawan, H., Tjandra, K. C., Respati, D. R. P., Rampengan, D. D. C. H., Ramadhan, R. N., Jangkang, G. G., Mahati, E., & Winona, P. (2025). The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysis. PLOS One. https://doi.org/10.1371/journal.pone.0307128

Vancouver

Adrianto AA, Riwanto I, Sadhana U, Paramita DK, Setyawan H, Tjandra KC, et al. The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysis. PLOS One. 2025. doi:10.1371/journal.pone.0307128

BibTeX
@article{Adrianto2025,
  author = {Adrianto, Albertus Ari and Riwanto, Ignatius and Sadhana, Udadi and Paramita, Dewi Kartikawati and Setyawan, Henry and Tjandra, Kevin Christian and Respati, Danendra Rakha Putra and Rampengan, Derren David Christian Homenta and Ramadhan, Roy Novri and Jangkang, Gastin Gabriel and Mahati, Endang and Winona, Patricia},
  title = {The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysis},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0307128}
}
Kostenlos starten →